Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Passes Above 200 Day Moving Average – Time to Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.27 and traded as high as $4.68. Sonoma Pharmaceuticals shares last traded at $4.68, with a volume of 75,668 shares.

Sonoma Pharmaceuticals Price Performance

The firm has a market cap of $7.68 million, a PE ratio of -1.90 and a beta of 1.39. The firm has a 50-day simple moving average of $3.90 and a 200 day simple moving average of $3.27.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.14. Sonoma Pharmaceuticals had a negative net margin of 23.87% and a negative return on equity of 50.00%. The firm had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.26 million. Sell-side analysts forecast that Sonoma Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Heron Bay Capital Management purchased a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned about 2.06% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.